Inhibition of the Metastasis of Lewis Lung Carcinoma by Antibody Against Urokinase-Type Plasminogen Activator in the Experimental and Spontaneous Metastasis Model

Summary

A selective inhibitory antibody, raised against human high molecular weight urokinase-type plasminogen activator (HMW-uPA), was examined to determine whether it would inhibit production of experimental and spontaneous lung metastasis by murine Lewis lung carcinoma (3LL) cells. Polyclonal antibody to human uPA cross-reads with the murine uPA and inhibits murine uPA activity. When examined with an in vitro assay system using a modified Boyden chamber, the anti-catalytic IgG to uPA suppressed the invasion of tumor cells through Matrigel. Anti-uPA IgG inhibited neither the cell proliferation nor the binding of tumor cells to Matrigel, and showed no significant suppression of chemotactic migration of tumor cells to tibronectin. In an in vivo spontaneous metastasis assay, multiple subcutaneous (s. c.) injections of anti-uPA IgG (up to a concentration of 200 pg [ 500 inhibitory unit/mousc/day]) for 7 days immediately after s. c. tumor cell inoculation significantly inhibited the formation of lung metastasis in C57BL/6 mice in a dose-dependent manner. The inhibition of lung metastasis was not due to direct antitumor effects of anti-uPA IgG. In an in vivo experimental metastasis assay, multiple s. c. injections of anti-uPA IgG for 7 days after intravenous (i. v.) tumor cell inoculation did not reduce the number of lung tumor colonies. These results suggest that uPA more efficiently regulates the mechanism involved in the entry into vascular circulation of tumor cells (intravasation) than in extravasation, during the metastatic process.

• References

• 1 Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen PI, Nielsen LS, Shiver L. Plasminogen activators tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266
• 2 Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636-49
• 3 Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437-45
• 4 Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-9
• 5 Ossowski L, Reich E. Experimental model for quantitative study of metastasis. Cancer Res 1980; 40: 2300-9
• 6 Mignatti P, Robbins E, Rifkin DB. Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 1986; 47: 489-98
• 7 Gehlsen FR, Wagner NH, Hendrix MJC. Membrane Invasion Culture System (MICS). Med Instrum 1984; 18: 268-71
• 8 Kieinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, Martin GR. Basement membrane complexes with biological activity. Biochemistry 1986; 25: 312-8
• 9 Terranova VP, Hujanen ES, Martin GR. Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 1986; 77: 311-6
• 10 Albini A, Iwamoto Y, Kieinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45
• 11 Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R. Effects of inhibitors of plasminogen activator serine proteases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48: 3307-12
• 12 Gehlsen KR, Argraves WS, Pierschbacher MD, Rouslahti E. Inhibition of in vitro cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 1988; 106: 925-30
• 13 Shiver L, Larsson LI, Kielberg V, Nielsen LS, Andreasen PB. Imrnuno- cytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984; 99: 752-7
• 14 Sugiura K, Stock CC. Studies in a tumor spectrum. III. The effect of phos- phoramides on the growth of a variety of mouse and rat tumors. Cancer Res 1955; 15: 35-51
• 15 Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988; 48: 1270-8
• 16 Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies- The effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274-81
• 17 Strickland S, Beers WH. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins cyclic nucleotides and prostaglandins. J Biol Chem 1976; 251: 5694-702
• 18 Mira y Lopez R, Ossow'ski L. Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness. Cancer Res 1987; 47: 3558-64
• 19 Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Giinzler WA, Janicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 1991; 266: 5147-52
• 20 Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase- type plasminogen activator and cathepsin B. Cancer Res 1992; 52: 3610-4
• 21 Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F. Autocrine saturation of prourokinase receptors on human A431 cells. Cell 1986; 45: 675-84
• 22 Corti A, Nolli ML, Cassani G. Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immunoadsorbent-amidolytic assay (IAA). Thromb Haemostas 1986; 56: 407-10
• 23 Rouslahti E, Hayman EG, Pierschbacher M, Engvall E. Fibronectin: Purification immunochemical properties and biological activities. Methods in Enzymol 1982; 82: 828-31
• 24 Redwood SM, Liu BC-S, Weiss R, Hodge DE, Droller MJ. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer Res 1992; 69: 1212-9
• 25 Fidler IJ. Selection of successive tumor lines for metastasis. Nature (Lond) 1973; 242: 148-9
• 26 Solberg H, Lober D, Eriksen J, Ploug M, Ronne E, Behrendt N, Dano K, Hoyer-Hansen G. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur J Bio chem 1992; 205: 451-8
• 27 Cajot JF, Schleuning WD, Medcalf RL, Bamat J, Testus J, Liebermann L, Sordat B. Mouse L cells expressing human prourokinase-type plasminogen activator: Effects on extracellular matrix degradation and invasion. J Cell Biol 1989 109: 915-25
• 28 Yagel S, Warner AH, Nellans HN, Lala PK, Waghorne C, Denhardt DT. Suppression by cathepsin L inhibitors of the invasion of amniotic membranes by murine cancer cells. Cancer Res 1989; 49: 3553-7
• 29 Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond) 1980; 284: 67-8
• 30 Nakajima M, Welch DR, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987; 47: 4846-53
• 31 Thorgeirsson UP, Liotta LA, Kalebic T, Margulies IM, Thomas K. RiosCandelore M. Russo RG. Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro. J Natl Cancer Inst 1982; 69: 1049-54
• 32 Ostrowski LE, Ahsan A, Suthar BP, Pagast P, Bain DL, Wong C, Patel A, Schultz RM. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res 1986; 46: 4121-8
• 33 Polley MJ, Phillips ML, Wayner E, Nudelman E, Singhal AK, Hakomori S, Paulson JC. CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand sialyl Lewis x. Proc Natl Acad Sei USA 1991; 88: 6224-8
• 34 Beekhuizen H, Corsel-Van Tilburg AJ, Blokland I, Van Furth R. Characterization of the adherence of human monocytes to cytokine-stimulated human macrovascular endothelial cells. Immunol 1991; 74: 661-9
• 35 Lauri D, Martin-Padura I, Biondelli T, Rossi G, Bemasconi S, Giavazzi R, Passerini F, Van Hinsbergh V, Dejana E. Role of Bl-integrins in tumor cell adhesion to cultured human endothelial cells. Lab Invest 1991; 65: 525-31